Randomized Controlled Pilot Study of Antiretrovirals and a Behavioral Intervention for Persons with Acute HIV Infection: Opportunity for Interrupting Transmission by Miller, William C. et al.
M A J O R  A R T I C L E
RCT of ART and Behavioral Intervention for AHI • ofid • 1
Open Forum Infectious Diseases
Received 29 August 2018; editorial decision 10 December 2018; accepted 18 December 2018.
Correspondence: W.  C. Miller, MD, PhD, MPH, College of Public Health, The Ohio State 
University, 302 Cunz Hall, Columbus, OH 43210 (miller.8332@osu.edu).
Open Forum Infectious Diseases®
© The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases 
Society of America. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/
by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any 
medium, provided the original work is not altered or transformed in any way, and that the 
work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/ofid/ofy341
Randomized Controlled Pilot Study of Antiretrovirals and 
a Behavioral Intervention for Persons With Acute HIV 
Infection: Opportunity for Interrupting Transmission
William C. Miller,1,2,  Sarah E. Rutstein,3 Sam Phiri,4 Gift Kamanga,5 Dominic Nsona,4 Dana K. Pasquale,2 Katherine B. Rucinski,2 Jane S. Chen,2  
Carol E. Golin,6 Kimberly A. Powers,2 Ann M. Dennis,3 Mina C. Hosseinipour,3 Joseph J. Eron,3 Wairimu Chege,7 Irving F. Hoffman,3 and Audrey E. Pettifor2
1Division of Epidemiology, The Ohio State University, Columbus, Ohio; 2Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 3Division of Infectious 
Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 4Lighthouse Trust, Lilongwe, Malawi; 5UNC Project, Lilongwe, Malawi; 6Department of Health Behavior, University 
of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 7Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 
Background. Persons with acute HIV infection (AHI) have heightened transmission risk. We evaluated potential transmission 
reduction using behavioral and biomedical interventions in a randomized controlled pilot study in Malawi.
Methods. Persons were randomized 1:2:2 to standard counseling (SC), 5-session behavioral intervention (BI), or behavioral 
intervention plus 12 weeks of antiretrovirals (ARVs; BIA). All were followed for 26–52 weeks and, regardless of arm, referred for 
treatment according to Malawi-ARV guidelines. Participants were asked to refer partners for testing.
Results. Among 46 persons (9 SC, 18 BI, 19 BIA), the average age was 28; 61% were male. The median viral load (VL) was 5.9 
log copies/mL at enrollment. 67% (10/15) of BIA participants were suppressed (<1000 copies/mL) at week 12 vs 25% BI and 50% SC 
(P = .07). Although the mean number of reported condomless sexual acts in the past week decreased from baseline across all arms 
(1.5 vs 0.3 acts), 36% experienced incident sexually transmitted infection by 52 weeks (12% SC, 28% BI, 18% BIA). Forty-one percent 
(19/46) of participants referred partners (44% SC, 44% BI, 37% BIA); 15 of the partners were HIV-infected.
Conclusions. Diagnosis of AHI facilitates behavioral and biomedical risk reduction strategies during a high-transmission period 
that begins years before people are typically identified and started on ARVs. Sexually transmitted infection incidence in this cohort 
suggests ongoing risk behaviors, reinforcing the importance of early intervention with ARVs to reduce transmission. Early diagnosis 
coupled with standard AHI counseling and early ARV referral quickly suppresses viremia, may effectively change behavior, and 
could have tremendous public health benefit in reducing onward transmission.
Keywords.  acute HIV infection; HIV; Malawi; motivational interviewing; transmission.
Acute HIV infection (AHI) is the earliest possible period for 
HIV diagnosis, before emergence of HIV-specific antibodies 
[1]. The unchecked viral replication and high viral loads that 
occur in this phase, coupled with people being unaware of their 
infected status even if tested, results in AHI contributing a dis-
proportionate share of all new infections, as compared with 
chronic infection [2–6]. Efforts to limit transmission during 
the high-risk AHI phase face several challenges: (1) persons 
with AHI must present for testing shortly after acquiring the 
virus; (2) during testing, they must be tested specifically for 
AHI, incorporating either a test for HIV p24 antigen with 
a fourth-generation enzyme-linked immunosorbent assay 
(ELISA) or HIV RNA, because third-generation ELISA and 
most rapid antibody tests do not detect persons with very early 
infection; (3) after diagnosis, persons with AHI must either 
alter behavior rapidly or initiate antiretroviral therapy immedi-
ately in an attempt to lower infectiousness [7]. Taken together, 
these challenges represent a significant obstacle to the control of 
the HIV epidemic, especially in resource-limited settings.
In Malawi, we have successfully implemented routine test-
ing for AHI within the context of clinical research for 15 years 
[8–11]. Recently, we expanded AHI screening to multiple sex-
ually transmitted infection (STI) clinics and HIV testing and 
counseling (HTC) centers, demonstrating the feasibility of 
scaling up testing for AHI in an urban center [12]. Within this 
expanded testing, we embedded a randomized pilot study with 
the following primary objectives: (1) to evaluate the feasibility 
and acceptability of a behavioral intervention among persons 
with AHI and (2) to evaluate the feasibility and acceptability 
of short-term ARV use among persons with AHI. Secondary 
objectives were (1) to explore the effect of the interventions on 
HIV transmission risk behaviors; (2) to explore the effect of 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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the interventions on uptake of partner HIV testing; and (3) to 
explore the effect of short-term preventative ARV use on mark-
ers of infectivity and resistance. This study was implemented 
within the context of the Malawian treatment guidelines in place 
at the time of this study, which included Option B+ for pregnant 
women and antiretroviral therapy (ART) initiation at a CD4 
count of 350 cells/mL for men and nonpregnant women [13].
METHODS
Study Population and Setting
We screened for AHI at 2 STI and 2 HTC clinics in Lilongwe, 
Malawi. Enrollment and follow-up were completed between 
June 2012 and August 2014. AHI was defined as a detectable 
HIV RNA and a negative or discordant HIV antibody test. Per 
Malawi HIV testing algorithms, antibody testing included serial 
testing using Alere Determine HIV-1/2 (Alere) and Uni-Gold 
Recombigen HIV-1/2 (Trinity Biotech), with a tiebreaker for dis-
cordant results. Persons with 2 positive results were considered 
HIV-seropositive. Fingerstick specimens were tested for HIV 
RNA using a previously validated 9:1 pooling algorithm [14–16].
By protocol, persons with AHI were traced within 21 days of 
screening and asked to report to the clinic for test results. All 
successfully traced persons were given AHI-specific standard-
ized post-test counseling, including information about AHI, 
and given the opportunity to enroll in the study.
Eligibility criteria for enrollment included documentation 
of a negative or discordant rapid HIV test and positive RNA 
within 21 days of enrollment, age ≥18 years, and intention to 
remain in the Lilongwe area for the duration of study follow-up 
(52 weeks). We excluded persons with a serious illness requir-
ing systemic treatment or hospitalization, any drug or alcohol 
dependence that would interfere with adherence to study activ-
ities, or a history of imprisonment.
Primary participants were asked to refer sexual partners at 
any point during study follow-up for HIV testing using referral 
cards. To be eligible, partners had to bring the referral cards to 
1 of the study clinics and be ≥18 years old. Partners with AHI 
were not co-enrolled as primary and partner participants.
The National Health Sciences Research Committee of Malawi, 
the Malawi Medicines and Poisons Board, the Biomedical 
Institutional Review Board at the University of North Carolina, 
Chapel Hill, and the National Institute of Allergy and Infectious 
Diseases’ Prevention Science Review Committee approved all 
of the procedures for this study. All study participants provided 
written informed consent in the local language or English, 
if preferred. This study is registered at ClinicalTrials.gov 
(NCT01450189).
Study Arms and Randomization
Primary participants were randomized in a 1:2:2 ratio to 1 
of 3 groups: (1) standard counseling (SC); (2) a multisession 
behavioral intervention (BI); and (3) the same multisession 
behavioral intervention plus antiretrovirals (ARVs; BIA). We 
used blocked randomization with block sizes of 5, stratified by 
gender. Eligibility for ARV use, described below, was assessed 
after randomization to allow determination of the potential 
impact of the treatment regimen at a population level. All par-
ticipants were referred for routine HIV care [17]. Participants 
not on study ARVs were asked to self-report ARV initiation that 
occurred outside of study drug distribution.
SC
Primary participants randomized to the SC group received a 
single standard post-test counseling session, encouraged to 
reduce transmission risk by reducing the number of sexual 
partners and using condoms consistently and correctly, and 
given supplemental information about AHI.
BI
The behavioral intervention was developed by adapting features 
of the Options Project [18] and Project SafeTalk [19–21]—
interventions that have been shown to effectively reduce sexual 
risk behavior among people living with HIV [10]. Counseling 
sessions were delivered using a motivational interviewing–
based approach [11, 22]. The intervention comprised 5 sessions 
within 8 weeks of enrollment: the first 4 early intervention 
behavioral sessions were at day 0, day 3, week 1, and week 2, 
with the fifth (booster) session at week 8.
These 5 sessions were designed to provide participants with 
the information, motivation, and skills needed to abstain from 
or practice protected sex during the brief 12-week acute HIV 
period, as well as plan for long-term behavioral risk reduction. 
Counselors worked with participants to develop patient-cen-
tered short-term risk reduction goals and strategies to achieve 
those goals. The booster session (week 8) emphasized articulat-
ing a long-term risk reduction plan.
BIA
In addition to the behavioral intervention, persons in the BIA 
group received a 12-week course of raltegravir (400  mg by 
mouth, twice daily) and emtricitabine/tenofovir (FTC/TDF; 
200/300 mg by mouth, daily) beginning on day 3. The duration 
of therapy, 12 weeks, was based on a small trial that observed a 
reduction in HIV RNA levels in semen to undetectable using an 
unboosted protease inhibitor and results of a single-arm study 
in the North Carolina STAT Program for acute infection [23, 
24]. Exclusion criteria for ARVs included hepatitis B surface 
antigen positivity, anemia, neutropenia, thrombocytopenia, 
renal or liver dysfunction, pregnancy, breastfeeding, known 
hypersensitivity to selected ARVs, or need for a contraindicated 
medication. Participants excluded from study ARVs within the 
BIA arm remained in the arm in an intention-to-treat design. 
Based on accepted practice at the time of this study, the ARV 
component of the intervention was not intended to provide 
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long-term HIV treatment, but rather to prevent transmission 
by reducing the viral load quickly.
Per the a priori protocol, ARVs were discontinued for any 
moderate (Grade 2) or worse toxicity, symptom, or laboratory 
abnormality, unless that abnormality was clearly unrelated to 
ARVs. ARVs could be discontinued at the discretion of the local 
investigator or clinician even if toxicity did not reach a specified 
grade. Integrase and reverse transcriptase (RT) genotypic resis-
tance testing was performed on baseline, week 14, and week 26 
samples. A safety and monitoring committee was charged with 
oversight of potential harms related to ARV resistance in the 
BIA group. ARV use in the BIA group would have been dis-
continued if the lower 95% confidence limit of the proportion 
of persons in the BIA arm with acquired resistance at 6 months 
exceeded 10%.
Study Visits: Laboratory and Clinical Evaluations
Primary participants in all groups had 10 scheduled visits over 
52 weeks. Participants in the BIA group had 3 additional visits 
immediately after ARV discontinuation. A  complete physical 
examination was conducted at enrollment. Genital ulcer exams 
were conducted quarterly, beginning at enrollment. All primary 
participants had repeat rapid HIV antibody tests at each visit 
until seroconversion was confirmed. Plasma HIV RNA was mea-
sured using Abbott RealTime HIV-1 Assay (Abbott Laboratories, 
Chicago, IL; m2000; reportable range of 40–10 000 000 copies/
mL) or COBAS AMPLICOR HIV-1 MONITOR Test, version 
1.5 (Roche Molecular Diagnostics,  Pleasanton, California; 
reportable range of 50–750 000 copies/mL). Plasma viral loads 
were assessed at each study visit. Immunological (absolute 
CD4+/CD8+ counts and percentages), STI (Chlamydia tracho-
matis [Ct], Neisseria gonorrhea [GC], using BD ProbeTec SDA 
assay, Franklin Lakes, New Jersey), Trichomonas vaginalis (Tv; 
BioMed InPouch TV, White City, Oregon), and herpes simplex 
virus type 2 (HSV-2; Focus Diagnostics HerpeSelect 2 ELISA 
IgG,  Cypress, California) testing was conducted at entry and 
quarterly thereafter. STIs were treated upon diagnosis. Women 
received pregnancy testing every 4 weeks for the first quarter 
and quarterly thereafter.
Partner participants received HIV antibody testing at the 
time of presentation. HIV-seropositive partners had specimens 
collected for phylogenetic linkage and were not followed fur-
ther. Partners with negative or discordant rapid antibody test 
results were screened for AHI. Partners who were confirmed 
uninfected or who were identified as having AHI were followed 
quarterly for the duration of the primary participant’s enroll-
ment, during which they received rapid HIV tests and AHI 
screening (if HIV-negative at the time of enrollment), as well as 
STI testing (if AHI- or HIV-negative at the time of enrollment). 
Partners who seroconverted after a previously negative test had 
plasma HIV RNA levels assessed. All partners with HIV infec-
tion were referred for routine HIV care.
Questionnaires
Participants completed questionnaires at each study visit using 
audio computer-assisted self-interview (ACASI) software. 
Content included demographics, sexual risk behaviors (includ-
ing information on sexual partners), assessment of the con-
fidence they felt for and the importance they placed on HIV 
disclosure and sexual risk reduction, and knowledge regarding 
acute and established HIV infection.
Analysis
All analyses were performed using Stata (version 13.0; 
StataCorp, College Station, TX) and SAS (version 9.4; SAS 
Institute Inc.  Cary, NC). We conducted descriptive intention-
to-treat analyses by intervention arm (SC, BI, BIA) for all out-
comes. The Fisher exact test was used to compare the differences 
in proportions between arms for categorical variables, and t tests 
were used for continuous data. Differences were considered sta-
tistically significant when P values were <.05. We examined the 
cumulative incidence of a composite STI outcome of chlamydial 
infection, gonorrhea, or trichomoniasis at 12, 26, and 52 weeks.
RESULTS
Screening and Enrollment
A total of 9280 HIV-seronegative persons, including 55 (0.6%) 
with discordant rapid test results, were screened for AHI, and 
59 persons were identified with AHI, a prevalence of 0.64% 
among those who were HIV-seronegative for HIV [12]. In the 
4 weeks before screening, persons identified with AHI reported 
symptoms including genital ulcers or sores (42%), body aches 
(29%), fever (24%), and diarrhea (10%), which were all signifi-
cantly more prevalent than in persons without AHI. Fifty-eight 
(98%) were successfully traced within the protocol-defined 
21 days of AHI testing (median [range], 7 [4–17] days) (Figure 
1). Forty-six of 58 (79%) were enrolled in this pilot study, with 
9 participants randomized to the SC arm, 18 participants to the 
BI arm, and 19 participants to the BIA arm. Of the 21% who did 
not participate, all were eligible but refused further participa-
tion; no additional information is available regarding reason for 
refusal. Of the 46 participants, 14 (30%) were positive by both 
Determine and Uni-Gold 2 weeks after enrollment, 12 (26%) 
were positive by Determine only, and 15 (32%) were negative by 
Determine; 5 did not have rapid testing performed at 2 weeks.
Baseline Population Characteristics
The mean age of persons with AHI enrolled was 28 years. More 
men than women were enrolled (61% vs 39%, respectively) 
(Table 1), consistent with the proportion of men and women 
identified with AHI. Among those who reported at least 1 part-
ner (n  =  38), 32 (84%) reported no condom use. The overall 
median viral load (interquartile range [IQR]) was 5.9 (5.2–6.5) 
log10 copies/mL. Sociodemographic characteristics were similar 
across study arms.
4 • ofid • Miller et al
Behavioral Intervention
The acceptability of the behavioral intervention was measured 
through the uptake of the intervention. Overall, 81% (30/37) 
of BI and BIA participants completed all 4 early intervention 
behavioral sessions, 28 (76%) of whom did so within 3 weeks of 
enrollment. The median time to session completion (IQR) was 
16 (14–18) days.
We assessed the impact of the behavioral intervention on sex-
ual HIV risk behavior by examining self-reported unprotected 
sex acts and STI incidence in each arm over the 52-week study 
period. Among all participants (SC, BI, or BIA) with data avail-
able, the mean number of unprotected sex acts in the past week 
was 1.5 (SD, 3.0; n = 44) at week 0, 0.7 (SD, 1.9; n = 36) at 12 
weeks, and 0.3 (SD, 1.0; n = 25) at 52 weeks (Figure 2). A simi-
lar downward trend was observed when evaluating unprotected 
sex acts in the previous month. No meaningful difference was 
discernable across arms.
As an alternative measure of unprotected sex, we examined 
the cumulative incidence of a composite STI measure at 12, 26, 
and 52 weeks. Across all groups, the cumulative incidence was 
15% (95% confidence interval [CI], 4%–25%) at 12 weeks, 22% 
(95% CI, 10%–35%) at 26 weeks, and 38% (95% CI, 21%–53%) 
at 52 weeks. The incidence was highest, although not statisti-
cally significantly so, in the BI arm (25% at 12 weeks, 31% at 26 
weeks, 47% at 52 weeks) compared with SC (13% at 12 weeks, 
13% at 26 weeks, 25% at 52 weeks) and BIA (6% at 12 weeks, 
19% at 26 weeks, and 35% at 52 weeks). For HSV-2, 13 were 
negative at baseline; 4 of 10 with available results seroconverted 
by 26 weeks (SC 1, BI 2, BIA 1) and another 1 (BI) by 52 weeks.
Antiretroviral Intervention
Among the 19 persons assigned to the BIA arm, 12 ini-
tiated study ARV. Among those who did not initiate study 
ARV, 1 withdrew before initiation, 2 were breastfeeding and 
were referred to initiate Malawi firstline ARVs, and 4 were 
excluded due to hepatitis B surface antigen test positivity. 
Among the 12 who initiated study ARV, 10/10 with available 
week 12 results had a VL <1000 copies/mL, and 9/10 had a VL 
<50 copies/mL (Figure 3). Three of 6 participants in the BIA 
arm who were retained in the study but not initially eligible 
Screened for AHI
(n = 9280)a
(STI: 6456; HTC 5025)
Confirmed HIV-negative
(n = 9105)
(STI: 4160; HTC: 4945)
Detectable HIV RNA
(n = 66)
(STI: 49; HTC: 17)
Established infectionb
(n = 7)
(STI: 5; HTC: 2)
Untraceable
(n = 1)
Assessed for eligibility
(n = 58)
Enrolled and randomized
(n = 46)
Declined participation
(n = 12)
SC
(n = 9)
BI
(n = 18)
BIA
(n = 19)
AHI
(n = 59)
(STI: 44; HTC: 15)
Figure 1. Participant screening, enrollment, and allocation to study arm. aBlood was not collected for 12 consenting participants; another 97 participants had insufficient 
volume for testing or the specimen clotted before testing. bFalse-negative antibody test from screening was confirmed on laboratory retest. Abbreviations: AHI, acute HIV 
infection; BI, behavioral intervention; BIA, behavioral intervention plus treatment; HTC, HIV testing and counseling; SC, standard counseling; STI, sexually transmitted infection.
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for the study drug (2 breastfeeding and 1 HBV-positive) were 
started on firstline ARVs during the study follow-up period 
(weeks 4, 8, and 26, respectively); 1 of the 2 who were on stan-
dard firstline treatment by week 12 had a VL <1000 copies/
mL at the week 12 visit. At week 26 (approximately 14 weeks 
off of the study drug), 10/12 who had been on the study drug 
had their VL rebound (VL >1000 copies/mL); the other 2 
remained suppressed (255 copies/mL and <40 copies/mL) 
despite being off ARVs. Two BIA participants who received 
the 12-week study ARV were started on firstline ARVs later 
in their 52-week follow-up, 1 based on CD4 eligibility. We 
could not identify a reason for treatment initiation for the 
other with available data.
Among the 27 persons in the SC and BI arms, 4 initiated 
ARVs during the first 12 weeks (SC 2, BI 2; indications: 1 
breastfeeding, 1 low CD4, 2 not specified); all 4 were virally 
suppressed at week 12. Five initiated ARVs later in follow-up 
(indication: 1 low CD4, 1 pregnancy, remainder not speci-
fied), and 3 were suppressed to <1000 copies/mL before study 
completion.
Among participants with available VL data, week 12 viral 
suppression was greatest in the BIA group (BIA 11/15, 73% [11 
on therapy]; BI 4/16, 25% [2 on therapy]; SC 3/6, 50% [2 on 
therapy]; P  =  .07). Across all groups, 49% (18/37) of persons 
with available VLs were suppressed to <1000 copies/mL at week 
12; 15/18 were on therapy. After accounting for missing data by 
Table 1. Basic Demographics and Baseline Behavioral Characteristics
Overall(n = 46) SC(n = 9) BI(n = 18) BIA(n = 19)
No. (%) No. (%) No. (%) No. (%)
Age, ya
 18–24 19 (41) 2 (22) 8 (44) 9 (47)
 25–34 20 (43) 4 (44) 8 (44) 8 (42)
 35–44 6 (13) 3 (33) 2 (11) 1 (5)
 ≥45 1 (2) 0 (0) 0 (0) 1 (5)
Sex
 Male 28 (61) 5 (56) 11 (61) 12 (63)
 Female 18 (39) 4 (44) 7 (39) 7 (37)
Education
≤ primary completed 26 (57) 6 (67) 8 (44) 12 (63)
Some secondary 12 (26) 1 (11) 5 (28) 6 (32)
≥ secondary completed 8 (17) 2 (22) 5 (28) 1 (5)
Employment status
 Employed 30 (65) 7 (78) 11 (61) 12 (63)
Not employed 16 (35) 2 (22) 7 (39) 7 (37)
Marital status
Never married 11 (24) 3 (33) 6 (33) 2 (11)
 Married 23 (50) 4 (44) 8 (44) 11 (58)
 Divorced/separated/widowed 12 (26) 2 (22) 4 (22) 6 (32)
Total partners (previous 4 wk)b
 0 7 (16) 2 (22) 1 (6) 4 (21)
 1 27 (60) 6 (67) 9 (53) 12 (63)
 ≥2 11 (24) 1 (11) 7 (41) 3 (16)
Condom use (previous 4 wk)c
 None 19 (43) 5 (56) 7 (44) 7 (37)
 Some 12 (27) 2 (22) 4 (25) 6 (32)
Every time 6 (14) 0 (0) 4 (25) 2 (11)
No sex reported 7 (16) 2 (22) 1 (6) 4 (21)
Total partners (previous 1 wk)b
 0 22 (49) 4 (44) 12 (71) 6 (32)
 1 19 (42) 4 (44) 4 (24) 11 (58)
 ≥2 4 (9) 1 (11) 1 (6) 2 (11)
Viral loadb
≤6.0 log10 copies/mL 24 (53) 5 (56) 7 (41) 12 (63)
>6.0 log10 copies/mL 21 (47) 4 (44) 10 (59) 7 (37)
Abbreviations: BI, behavioral intervention; BIA, behavioral intervention plus treatment; SC, standard counseling.
aMean age (SD), 28 (7) years.
bn = 45.
cn = 44.
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using the closest visit with an available RNA specimen, the pro-
portion with a VL <1000 was more pronounced (20/42, 48%; 
BIA 13/18, 72%; SC 3/8, 38%; BI 4/16, 25%; P = .02).
After treatment interruption at 12 weeks, viral rebound was 
observed in all but 1 of the BIA arm participants, who received 
and then stopped study-provided ARV by week 16 (Figure 3). 
Rebound >106 copies/mL was seen in 2 participants; 1 of these 
was substantially delayed. Viral setpoints after discontinuation 
were comparable to the other arms.
One woman in the BIA arm was considered an elite suppres-
sor. At screening, her VL was 13 780 copies/mL with a posi-
tive Determine and a negative Uni-Gold antibody test. Her VL 
declined before ART (Figure 3), and at the conclusion of the 
study, she was undetectable off of ART with negative Determine 
and Uni-Gold tests.
We examined antiretroviral resistance in the BIA arm at 
weeks 0, 14, and 26 (Table 2). None of the participants in this 
study had documented new mutations as a result of study treat-
ment, although approximately half of the samples at week 14 
did not amplify due to low HIV RNA levels. On or after week 
14, 5 participants had a non-nucleoside reverse transcriptase 
inhibitor mutation, 2 had an nucleoside reverse transcriptase 
inhibitor mutation, and 1 had an integrase strand transfer 
inhibitor accessory mutation: all mutations detected were pres-
ent at week 0.
Partner Referrals and Transmission
Among 46 participants, 19 (41%) referred partners for evalua-
tion, representing 14% of all reported sexual partners (n = 136) 
in the 52-week follow-up period. No participants referred >1 
partner. The percentage of participants referring a partner was 
similar across arms (SC 44%, BI 44%, BIA 37%). All 19 partners 
reporting for evaluation agreed to HIV testing; 15/19 (79%) had 
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Figure 3. Log10 viral load by study arm. Median, mean, and individual viral 
loads are shown. Viral load for one elite suppressor in the BIA arm is also shown. 
Abbreviations: BI, behavioral intervention; BIA, behavioral intervention plus treat-
ment; SC, standard counselling; VL, viral load.
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Figure 2. Mean number of condomless sex acts over the previous month (left) or previous week (right) over the course of the study, by study arm. Abbreviations: BI, behav-
ioral intervention; BIA, behavioral intervention plus treatment; SC, standard counseling.
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established HIV infection, 1 (5%) had acute HIV infection (BI 
index, partner diagnosed with AHI 26 weeks into index par-
ticipant follow-up), 1 (5%) seroconverted during the study (SC 
index, partner diagnosed 13 weeks into index participant fol-
low-up), and 2 (10%) remained seronegative. All but 1 partner 
(13/14, 93%) were phylogenetically linked to the referring par-
ticipant [25].
DISCUSSION
In this study, we assessed the potential public health benefit of 
intervening during the brief window of AHI to prevent HIV 
transmission. We successfully identified persons with AHI and 
engaged them in behavioral and antiretroviral-based interven-
tions. Reductions in viral load were achieved rapidly in the BIA 
arm, with more than a log10 difference by week 4 and suppres-
sion to <1000 in all participants eligible to receive study ARV. 
Most persons reported reduced sexual behavior risk, regardless 
of the intervention arm [10, 11, 22, 26].
This study is one of the first to explore AHI treatment in the 
Sub-Saharan African context, despite the focus on the feasi-
bility of early treatment as a means to prevent AHI-associated 
transmission [27]. In our study, we limited the treatment period 
to 12 weeks, given the absence of World Health Organization 
(WHO) guidelines for AHI treatment at the time and our 
emphasis on rapidly reducing viral load for the purposes of 
decreasing transmission. This approach is not consistent with 
current WHO recommendations to initiate and maintain 
therapy when people are diagnosed with HIV, including AHI, 
based on a universal treatment strategy [28]. This duration of 
treatment before interruption is also considerably shorter than 
most other studies of treatment interruption after acute/early 
infection, making it difficult to compare to those studies [29]. 
Nonetheless, the lessons learned remain pertinent, and rapid 
identification of persons with AHI followed by rapid ARV 
initiation remains relevant, especially as point-of-care tests 
capable of accurately detecting viral RNA in resource-limited 
settings become available.
Two-thirds of participants in the BIA arm achieved viral sup-
pression by 12 weeks after ARV initiation. Several participants 
in the BIA arm did not initiate ARV because of hepatitis B sur-
face antigen positivity to avoid exposure to a single active agent, 
tenofovir; this group would not be excluded from most treat-
ment guidelines. The proportion of VL suppression within 12 
weeks among those who actually received ARV was 100%. This 
rate of rapid viral suppression during AHI is comparable to that 
observed in the United States and Thailand [30, 31]. This rapid 
viral suppression is also consistent with a South African cohort 
study in which women were tested twice weekly for HIV using 
polymerase chain reaction by finger prick [27]. Immediate 
treatment for these women with Feibig stage I AHI led to viral 
suppression in <3 weeks. The rapid decline in viral load in our 
cohort may be due, in part, to use of an integrase inhibitor in 
the regimen—an alternative WHO firstline therapy that may 
soon be standard firstline in many Sub-Saharan African settings 
[32–35]. The initiation and subsequent discontinuation of ARV 
was not associated with any detectable antiretroviral resistance 
beyond what was present at baseline.
ARV use among persons in the other arms was common, due 
to both pregnancy/breastfeeding and CD4 eligibility. Overall, 
one-third (9/27) of persons in the non-ARV arms initiated ARV 
during study follow-up (up to 52 weeks for most); 4 started 
within 12 weeks of enrollment, but only 1 within the first 4 
weeks. Despite success in terms of viral suppression post–ARV 
initiation, the potential transmission interruption during AHI 
was only realized in a small fraction as most initiated therapy 
well outside of the acute window. We also noted that a few 
people appeared to have periods of viral suppression without 
reported ARV use. This finding is consistent with other lon-
gitudinal studies of AHI, in which about 8% of persons with 
AHI had spontaneous viral suppression in the first year after 
diagnosis [36]. Unfortunately, in our case, we were limited by 
the self-reported nature of nonstudy ARV initiation, which may 
have led to some misclassification.
After diagnosis, reporting of risky sexual behaviors was 
substantially reduced. Participants in all arms reported <1 
unprotected sex act per week after AHI diagnosis, a decrease 
that persisted through 52 weeks. This finding is consistent with 
HPTN 062, which used a similar behavioral intervention in 
Lilongwe [11]. The behavioral intervention was moderately 
acceptable, with about three-quarters of participants receiving 
the intervention within 3 weeks of enrollment. Nonetheless, the 
behavioral intervention (BI and BIA) appeared to have little if 
any additional protective effect beyond standard counseling on 
either reported condom use or STI acquisition. The standard 
counseling included specific information related to acute HIV 
infection, including the increased risk of transmission, which 
may have influenced behavior. At a minimum, we believe that 
Table 2. Antiretroviral Resistance in the BIA Arm
NRTI NNRTI
Integrase 
Inhibitors
No. (%) No. (%) No. (%)
Week 0a 2 (11) 5 (26) 0b (0)
Week 14c 0d (0) 2 (33) 0e (0)
Week 26f 2 (15) 3 (23) 0b (0)
Abbreviations: BIA, behavioral intervention plus treatment; NNRTI, non-nucleoside reverse 
transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; VL, viral load.
aNineteen participants were screened.
bAccessory integrase resistance was identified in 2 at week 0 and 1 at week 26 (week 0: 
L74I, H51Q; week 26: H51Q).
cTwelve participants were screened for NRTI and integrase inhibitor resistance; 6 were 
screened for NNRTI resistance.
dSix of 12 did not amplify; all VL <100 copies/mL.
eFive of 12 did not amplify; all VL <100 copies/mL.
fThirteen participants were screened.
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counseling for persons with AHI should emphasize the poten-
tial for early transmission, the need for partner notification 
and referral, and the importance of immediate ARV to prevent 
onward transmission [26].
The self-reported values of sexual behavior, despite the use 
of ACASI, may underestimate true levels of risk behavior [10]. 
Biological markers in the form of STI incidence indicate non-
trivial amounts of condomless sex—the cumulative incidence of 
chlamydial infection, gonorrhea, or trichomoniasis was nearly 
15% at 12 weeks and exceeded 20% at 26 weeks—suggesting that 
some persons continued to engage in behavior that could poten-
tially result in HIV transmission, even in the extremely high-risk 
3-month period after acquisition. Of course, STI incidence is not 
a perfect proxy for HIV transmission risk, as unprotected inter-
course between 2 HIV-infected persons does not carry any HIV 
transmission risk, a distinction we were unable to make here in the 
absence of information about every partner’s HIV status. Among 
the partners referred by ~40% of all participants (using passive 
partner notification), nearly 80% were already HIV-infected. 
However, 10% of the initially uninfected partners seroconverted 
after enrollment, indicating appreciable ongoing transmission risk 
in this cohort. The low yield of partners presenting via passive 
partner notification highlights the importance of active forms of 
partner services, especially to reach casual partners, with provid-
er-initiated partner notification as a more effective means of test-
ing partners and identifying new infections [37–40].
CONCLUSIONS
Despite challenges in identifying persons with AHI, once iden-
tified, they are generally readily linked into care and can quickly 
achieve viral suppression. Using STI incidence as a proxy for 
ongoing risk behaviors suggests that behavior change, partic-
ularly longer-term change, may have been less successful than 
self-reported measures indicate, emphasizing the importance of 
ARV initiation to reduce HIV transmission. The public health 
benefits of AHI detection and ARV initiation are not limited to 
transmission risk reduction in the weeks or months after HIV 
acquisition; this early detection and viral suppression could 
represent years’ worth of averted transmissions, as these per-
sons would otherwise be misdiagnosed as HIV-negative and 
potentially transmitting, not only during their acute phase but 
during established infection until they again sought testing ser-
vices. Ramping up “test and start” will likely have a substantial 
impact on transmission, but in the absence of testing algorithms 
that identify persons with AHI, “test and start” will successfully 
decrease the transmission rates only among persons with estab-
lished infection, ultimately increasing the contribution of AHI 
to the percentage of overall transmissions. Persons with AHI 
remain a critical population to identify and immediately treat, 
and we have demonstrated that both tasks are feasible even in 
resource-limited settings.
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